CXCR2 and neoplasm: These findings establish CXCL1 as a pivotal mediator of CAF differentiation through CXCR2-dependent signaling, and highlight that the CXCL1–CXCR2 axis is a promising therapeutic target for modulating stromal–tumor interactions in OSCC.